Adults hospitalized with RSV-associated ARI faced persistent long-term adverse outcomes when compared with those with influenza-associated ARI or no recent ARI.

SK bioscience will advance a novel respiratory syncytial virus (RSV) monoclonal antibody for global health under license from the Gates Medical Research Institute (Gates MRI).

Level of risk peaked in the week after a hospital admission but lingered through 6 months ...

Adults hospitalized with an acute respiratory syncytial virus (RSV) infection faced an increased risk of cardiorespiratory events such as heart attack or stroke in the weeks afterward, according to a ...

South Korean vaccine specialist SK bioscience has in-licensed a clinical-stage respiratory syncytial virus (RSV) preventive ...

Bacterial coinfections in adults hospitalized with RSV do not appear to exacerbate clinical outcomes or increase mortality rates.

This week in JAMA Network Open, a team led by researchers from respiratory syncytial virus (RSV) vaccine-maker Pfizer ...

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing medically attended infections and hospitalizations. Maternal vaccination and ...

Children under 2 years of age are at highest risk for getting critically ill from the flu or RSV and requiring intensive care. Currently, doctors can only provide breathing support for severe flu or ...

UK pharma major GSK today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has ...

AS01-adjuvanted RSV and shingles vaccines were tied to a lower dementia risk in older adults. Compared with flu vaccine recipients, those who had the AS01 RSV shot had 29% more dementia-free time over ...

For adults 45 and older, RSV raises the risk of heart attack and stroke, especially in the first 30 days of infection. A similar risk is observed in older adults who get the flu. Preventing severe RSV ...